H. Con. Res. 27, "Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025"
S. Con. Res. 11/H.Con.Res. 27, "An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025."
In the above, specifically potential pharmaceutical reimbursement cuts as potential offsets AND potential inclusion of Medicare coverage of FDA-approved obesity drugs.
S 1695 /HR3020 --FY 2016 Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act, specifically NDPP funding.
HR 2029 the FY 2016 Consolidated Appropriations Act; PL 114-113
HR 3660 Preventive Health Savings Act
HR 716/H.J.Res 61 Continuing Appropriation through 12/11/15 (PL114-53).
HR 1192/S 586 National Diabetes Clinical Care Commission Act of 2015
S 1695 / HR 3020 -- National Diabetes Prevention Program funding as part of the Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act for FY 2016
Implementation of the Affordable Care and Health Care & Education Affordability Reconciliation Act of 2010 (PL 111-148 and 111-152); diabetes screening
Human growth hormone, obesity and rare disease matters
HR 3742, Access to Marketplace Insurance Act
HR 2 - Medicare Access and CHIP Reauthorization Act of 2015
PL 114-10 -- Medicare Access and CHIP Reauthorization Act of 2015
S 1509 / HR 2404-- Treat and Reduce Obesity Act of 2015 -- Medicare coverage of FDA-approved obesity medications
HR 6 - 21st Century Cures Act
In the above measures, specifically potential pharmaceutical reimbursement cuts as potential offsets including potential changes to Part D as well as Medicare coverage for FDA-approved obesity medications.
HR 6 - 21st Century Cures Act
FDA issues regarding biosimilar products; 340B program matters
Duration: January 3, 2013
to
December 31, 2015
General Issues: Budget/Appropriations , Health Issues , Medicare/Medicaid , Pharmacy , Medical/Disease Research/Clinical Labs
Spending: about $288,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2013: U.S. Senate, House of Representatives
Affiliated organizations: Novo Nordisk A/S
Related Foreign Entities:
Novo Nordisk A/S (Copenhagen, DEN); contribution to lobbying: $0; ownership 100%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2015
SLC Health Strategies, LLC terminated an engagement in which they represented Novo Nordisk Pharmaceuticals, Inc. on Jan. 20, 2016.
Original Filing: 300781550.xml
Lobbying Issues
H. Con. Res. 27, "Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025"
S. Con. Res. 11/H.Con.Res. 27, "An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025."
In the above, specifically potential pharmaceutical reimbursement cuts as potential offsets AND potential inclusion of Medicare coverage of FDA-approved obesity drugs.
S 1695 /HR3020 --FY 2016 Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act, specifically NDPP funding.
HR 2029 the FY 2016 Consolidated Appropriations Act; PL 114-113
HR 3660 Preventive Health Savings Act
HR 716/H.J.Res 61 Continuing Appropriation through 12/11/15 (PL114-53).
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 1192/S 586 National Diabetes Clinical Care Commission Act of 2015
S 1695 / HR 3020 -- National Diabetes Prevention Program funding as part of the Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act for FY 2016
Implementation of the Affordable Care and Health Care & Education Affordability Reconciliation Act of 2010 (PL 111-148 and 111-152); diabetes screening
Human growth hormone, obesity and rare disease matters
HR 3742, Access to Marketplace Insurance Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 2 - Medicare Access and CHIP Reauthorization Act of 2015
PL 114-10 -- Medicare Access and CHIP Reauthorization Act of 2015
S 1509 / HR 2404-- Treat and Reduce Obesity Act of 2015 -- Medicare coverage of FDA-approved obesity medications
HR 6 - 21st Century Cures Act
In the above measures, specifically potential pharmaceutical reimbursement cuts as potential offsets including potential changes to Part D as well as Medicare coverage for FDA-approved obesity medications.
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 6 - 21st Century Cures Act
FDA issues regarding biosimilar products; 340B program matters
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, SLC Health Strategies, LLC lobbied for Novo Nordisk Pharmaceuticals, Inc. , earning $22,500. The report was filed on Oct. 19, 2015.
Original Filing: 300757256.xml
Lobbying Issues
H. Con. Res. 27, "Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025"
S. Con. Res. 11/H.Con.Res. 27, "An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025."
In the above, specifically potential pharmaceutical reimbursement cuts as potential offsets AND potential inclusion of Medicare coverage of FDA-approved obesity drugs.
S 1695 /HR3020 --FY 2016 Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act, specifically NDPP funding.
HR 3660 Preventive Health Savings Act
HR 716/H.J.Res 61 Continuing Appropriation through 12/11/15 (PL114-53).
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 1192/S 586 National Diabetes Clinical Care Commission Act of 2015
S 1695 / HR 3020 -- National Diabetes Prevention Program funding as part of the Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act for FY 2016
Implementation of the Affordable Care and Health Care & Education Affordability Reconciliation Act of 2010 (PL 111-148 and 111-152); diabetes screening
Human growth hormone, obesity and rare disease matters
Legislation (no bill number yet) regarding private not-for-profit foundations paying for health exchange premiums and cost sharing for certain individuals.
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 2 - Medicare Access and CHIP Reauthorization Act of 2015
PL 114-10 -- Medicare Access and CHIP Reauthorization Act of 2015
S 1509 / HR 2404-- Treat and Reduce Obesity Act of 2015 -- Medicare coverage of FDA-approved obesity medications
HR 6 - 21st Century Cures Act
In the above measures, specifically potential pharmaceutical reimbursement cuts as potential offsets including potential changes to Part D as well as Medicare coverage for FDA-approved obesity medications.
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 6 - 21st Century Cures Act
FDA issues regarding biosimilar products; 340B program matters
Agencies Lobbied
U.S. Senate
2nd Quarter, 2015
In Q2, SLC Health Strategies, LLC lobbied for Novo Nordisk Pharmaceuticals, Inc. , earning $22,500. The report was filed on July 20, 2015.
Original Filing: 300740583.xml
Lobbying Issues
H. Con. Res. 27, "Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025"
S. Con. Res. 11, "An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025."
In the above, specifically potential pharmaceutical reimbursement cuts as potential offsets AND potential inclusion of Medicare coverage of FDA-approved obesity drugs.
S 1695 /HR3020 --FY 2016 Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act (no bill number yet), specifically NDPP funding
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 1192/S 586 National Diabetes Clinical Care Commission Act of 2015
S 1695 / HR 3020 -- National Diabetes Prevention Program funding as part of the Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act for FY 2016
Implementation of the Affordable Care and Health Care & Education Affordability Reconciliation Act of 2010 (PL 111-148 and 111-152); diabetes screening
Human growth hormone, obesity and rare disease matters
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 2 - Medicare Access and CHIP Reauthorization Act of 2015
S 810 -SGR Repeal and Medicare Provider Payment Modernization Act of 2015
PL 114-10 -- Medicare Access and CHIP Reauthorization Act of 2015
S 1509 / HR 2404-- Treat and Reduce Obesity Act of 2015 -- Medicare coverage of FDA-approved obesity medications
HR 6 - 21st Century Cures Act
In the above measures, specifically potential pharmaceutical reimbursement cuts as potential offsets including potential changes to Part D as well as Medicare coverage for FDA-approved obesity medications.
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 6 - 21st Century Cures Act
FDA issues regarding biosimilar products; 340B program matters
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, SLC Health Strategies, LLC lobbied for Novo Nordisk Pharmaceuticals, Inc. , earning $22,500. The report was filed on April 20, 2015.
Original Filing: 300722250.xml
Lobbying Issues
H. Con. Res. 27, "Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025"
S. Con. Res. 11, "An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025."
In the above, specifically potential pharmaceutical reimbursement cuts as potential offsets AND potential inclusion of Medicare coverage of FDA-approved obesity drugs.
FY 2016 Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act (no bill number yet), specifically NDPP funding
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 1192/S 586 National Diabetes Clinical Care Commission Act of 2015
National Diabetes Prevention Program funding as part of the Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act for FY 2016 (no bill number yet)
Implementation of the Affordable Care and Health Care & Education Affordability Reconciliation Act of 2010 (PL 111-148 and 111-152); diabetes screening
Human growth hormone, obesity and rare disease matters
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 2., "Medicare Access and CHIP Reauthorization Act of 2015"
S. 810, "SGR Repeal and Medicare Provider Payment Modernization Act of 2015"
The Treat and Reduce Obesity Act of 2015 (no bill number yet) -- Medicare coverage of FDA-approved obesity medications
In the above measures, specifically potential pharmaceutical reimbursement cuts as potential offsets including potential changes to Part D as well as Medicare coverage for FDA-approved obesity medications.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FDA issues regarding biosimilar products; 340B program matters
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
In Q4, SLC Health Strategies, LLC lobbied for Novo Nordisk Pharmaceuticals, Inc. , earning $27,000. The report was filed on Jan. 19, 2015.
Original Filing: 300700649.xml
Lobbying Issues
FY 2014 Omnibus HR 3547
FY 2014 Continuing Resolution H J Res 106 PL 113-73
FY 2014 Continuing Resolution H J Res 59 PL 113-67
HR 4302 SGR Patch Protecting Access to Medicare Act of 2014 - Public Law No: 113-93
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
HR 962/S 452 Medicare Diabetes Prevention Act of 2013; HR 1257 - Prevent Diabetes in Medicare Act of 2013; HR 1247/S 945 - Access to Quality Diabetes Education Act of 2013; HR 2663/ S 1422 Scoring of Preventive Health Savings; and
S 1284 - Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act of 2014, specifically NDPP funding
HR 83 - Consolidated and Further Continuing Appropriations Act, 2015
Agencies Lobbied
U.S. Senate
Lobbying Issues
National Diabetes Prevention Program funding -- S 1284 - Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act of 2014
Implementation of the Affordable Care and Health Care & Education Affordability Reconciliation Act of 2010 (PL 111-148 and 111-152); diabetes screening
Human growth hormone and rare disease matters
HR 1074/S 539 - National Diabetes Clinical Care Commission Act of 2013
HR 1247/S 945 - Access to Quality Diabetes Education Act of 2013
HR 1915/S 907 - Gestational Diabetes Act of 2013
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2014 Omnibus HR 3547
FY 2014 Continuing Resolution H J Res 106 PL 113-73
FY 2014 Continuing Resolution H J Res 59 PL 113-67
HR 4302 SGR Patch Protecting Access to Medicare Act of 2014 - Public Law No: 113-93
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
HR 962/S 452 - Medicare Diabetes Prevention Act of 2013
HR 1257 Prevent Diabetes Medicare Act of 2013
HR 1274/S 945 Access to Quality Diabetes Education Act of 2013; HR 1588/ S 740 -- Medicare Drug Savings Act of 2013
HR 2415/ S 1184 - Treat and Reduce Obesity Act of 2013; HR 2663/S 1422 - Scoring of Preventive Health Savings
Medicare diabetes screening and self management
Agencies Lobbied
U.S. Senate
Lobbying Issues
FDA issues regarding biosimilar products; 340B program matters
Agencies Lobbied
U.S. Senate
3rd Quarter, 2014
In Q3, SLC Health Strategies, LLC lobbied for Novo Nordisk Pharmaceuticals, Inc. , earning $27,000. The report was filed on Oct. 19, 2014.
Original Filing: 300682390.xml
Lobbying Issues
FY 2014 Omnibus HR 3547
FY 2014 Continuing Resolution H J Res 106 PL 113-73
FY 2014 Continuing Resolution H J Res 59 PL 113-67
HR 4302 SGR Patch Protecting Access to Medicare Act of 2014 - Public Law No: 113-93
H Con Res 96 Establishing the budget for the United States Government for fiscal year 2015 and setting forth appropriate budgetary levels for fiscal years 2016 through 2024/no Senate companion yet
HJ Res 124 Continuing Appropriations Resolution, 2015
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
HR 962/S 452 Medicare Diabetes Prevention Act of 2013; HR 1257 - Prevent Diabetes in Medicare Act of 2013; HR 1247/S 945 - Access to Quality Diabetes Education Act of 2013; HR 2663/ S 1422 Scoring of Preventive Health Savings; and
S 1284 - Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act of 2014, specifically NDPP funding
Agencies Lobbied
U.S. Senate
Lobbying Issues
National Diabetes Prevention Program funding -- S 1284 - Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act of 2014
Implementation of the Affordable Care and Health Care & Education Affordability Reconciliation Act of 2010 (PL 111-148 and 111-152); diabetes screening
Human growth hormone and rare disease matters
HR 1074/S 539 - National Diabetes Clinical Care Commission Act of 2013
HR 1247/S 945 - Access to Quality Diabetes Education Act of 2013
HR 1915/S 907 - Gestational Diabetes Act of 2013
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2014 Omnibus HR 3547
FY 2014 Continuing Resolution H J Res 106 PL 113-73
FY 2014 Continuing Resolution H J Res 59 PL 113-67
HR 4302 SGR Patch Protecting Access to Medicare Act of 2014 - Public Law No: 113-93
H Con Res 96 Establishing the budget for the United States Government for fiscal year 2015 and setting forth appropriate budgetary levels for fiscal years 2016 through 2024/no Senate companion yet, HJ Res 124 Continuing Appropriations Resolution, 2015
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
HR 962/S 452 - Medicare Diabetes Prevention Act of 2013
HR 1257 Prevent Diabetes Medicare Act of 2013
HR 1274/S 945 Access to Quality Diabetes Education Act of 2013; HR 1588/ S 740 -- Medicare Drug Savings Act of 2013
HR 2415/ S 1184 - Treat and Reduce Obesity Act of 2013; HR 2663/S 1422 - Scoring of Preventive Health Savings
Medicare diabetes screening and self management
Agencies Lobbied
U.S. Senate
Lobbying Issues
FDA issues regarding biosimilar products; 340B program matters
Agencies Lobbied
U.S. Senate
2nd Quarter, 2014
In Q2, SLC Health Strategies, LLC lobbied for Novo Nordisk Pharmaceuticals, Inc. , earning $27,000. The report was filed on July 21, 2014.
Original Filing: 300664558.xml
Lobbying Issues
FY 2014 Omnibus HR 3547
FY 2014 Continuing Resolution H J Res 106 PL 113-73
FY 2014 Continuing Resolution H J Res 59 PL 113-67
HR 4302 SGR Patch Protecting Access to Medicare Act of 2014 - Public Law No: 113-93
H Con Res 96 Establishing the budget for the United States Government for fiscal year 2015 and setting forth appropriate budgetary levels for fiscal years 2016 through 2024/no Senate companion yet
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
HR 962/S 452 Medicare Diabetes Prevention Act of 2013; HR 1257 - Prevent Diabetes in Medicare Act of 2013; HR 1247/S 945 - Access to Quality Diabetes Education Act of 2013; HR 2663/ S 1422 Scoring of Preventive Health Savings; and
S 1284 - Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act of 2014, specifically NDPP funding
Agencies Lobbied
U.S. Senate
Lobbying Issues
National Diabetes Prevention Program funding -- S 1284 - Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act of 2014
Implementation of the Affordable Care and Health Care & Education Affordability Reconciliation Act of 2010 (PL 111-148 and 111-152); diabetes screening
Human growth hormone and rare disease matters
HR 1074/S 539 - National Diabetes Clinical Care Commission Act of 2013
HR 1247/S 945 - Access to Quality Diabetes Education Act of 2013
HR 1915/S 907 - Gestational Diabetes Act of 2013
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2014 Omnibus HR 3547
FY 2014 Continuing Resolution H J Res 106 PL 113-73
FY 2014 Continuing Resolution H J Res 59 PL 113-67
HR 4302 SGR Patch Protecting Access to Medicare Act of 2014 - Public Law No: 113-93
H Con Res 96 Establishing the budget for the United States Government for fiscal year 2015 and setting forth appropriate budgetary levels for fiscal years 2016 through 2024/no Senate companion yetIn all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
HR 962/S 452 - Medicare Diabetes Prevention Act of 2013
HR 1257 Prevent Diabetes Medicare Act of 2013
HR 1274/S 945 Access to Quality Diabetes Education Act of 2013; HR 1588/ S 740 -- Medicare Drug Savings Act of 2013
HR 2415/ S 1184 - Treat and Reduce Obesity Act of 2013; HR 2663/S 1422 - Scoring of Preventive Health Savings
Medicare diabetes screening and self management
Agencies Lobbied
U.S. Senate
Lobbying Issues
FDA issues regarding biosimilar products; 340B program matters
Agencies Lobbied
U.S. Senate
1st Quarter, 2014
In Q1, SLC Health Strategies, LLC lobbied for Novo Nordisk Pharmaceuticals, Inc. , earning $27,000. The report was filed on April 21, 2014.
Original Filing: 300646715.xml
Lobbying Issues
FY 2014 Omnibus HR 3547
FY 2014 Continuing Resolution H J Res 106 PL 113-73
FY 2014 Continuing Resolution H J Res 59 PL 113-67
HR 4302 SGR Patch Protecting Access to Medicare Act of 2014 - Public Law No: 113-93
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
HR 962/S 452 Medicare Diabetes Prevention Act of 2013; HR 1257 - Prevent Diabetes in Medicare Act of 2013; HR 1247/S 945 - Access to Quality Diabetes Education Act of 2013; HR 2663/ S 1422 Scoring of Preventive Health Savings; and
S 1284 - Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act of 2014, specifically NDPP funding
Agencies Lobbied
U.S. Senate
Lobbying Issues
National Diabetes Prevention Program funding -- S 1284 - Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act of 2014
Implementation of the Affordable Care and Health Care & Education Affordability Reconciliation Act of 2010 (PL 111-148 and 111-152); diabetes screening
Human growth hormone and rare disease matters
HR 1074/S 539 - National Diabetes Clinical Care Commission Act of 2013
HR 1247/S 945 - Access to Quality Diabetes Education Act of 2013
HR 1915/S 907 - Gestational Diabetes Act of 2013
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2014 Omnibus HR 3547
FY 2014 Continuing Resolution H J Res 106 PL 113-73
FY 2014 Continuing Resolution H J Res 59 PL 113-67
HR 4302 SGR Patch Protecting Access to Medicare Act of 2014 - Public Law No: 113-93
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
HR 962/S 452 - Medicare Diabetes Prevention Act of 2013
HR 1257 Prevent Diabetes Medicare Act of 2013
HR 1274/S 945 Access to Quality Diabetes Education Act of 2013; HR 1588/ S 740 -- Medicare Drug Savings Act of 2013
HR 2415/ S 1184 - Treat and Reduce Obesity Act of 2013; HR 2663/S 1422 - Scoring of Preventive Health Savings
Medicare diabetes screening and self management
Agencies Lobbied
U.S. Senate
Lobbying Issues
FDA issues regarding biosimilar products; 340B program matters
Agencies Lobbied
U.S. Senate
4th Quarter, 2013
In Q4, SLC Health Strategies, LLC lobbied for Novo Nordisk Pharmaceuticals, Inc. , earning $22,500. The report was filed on Jan. 21, 2014.
Original Filing: 300623410.xml
Lobbying Issues
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014
H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033
H. J. Res. 59 -- Continuing Appropriations Resolution, 2014
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
HR 962/S 452 Medicare Diabetes Prevention Act of 2013; HR 1257 - Prevent Diabetes in Medicare Act of 2013; HR 1247/S 945 - Access to Quality Diabetes Education Act of 2013; HR 2663/ S 1422 Scoring of Preventive Health Savings; and
S 1284 - Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act of 2014, specifically NDPP funding
Agencies Lobbied
U.S. Senate
Lobbying Issues
National Diabetes Prevention Program funding -- S 1284 - Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act of 2014
Implementation of the Affordable Care and Health Care & Education Affordability Reconciliation Act of 2010 (PL 111-148 and 111-152); diabetes screening
Human growth hormone and rare disease matters
HR 1074/S 539 - National Diabetes Clinical Care Commission Act of 2013
HR 1247/S 945 - Access to Quality Diabetes Education Act of 2013
HR 1915/S 907 - Gestational Diabetes Act of 2013
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014
H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033
H. J. Res. 59 -- Continuing Appropriations Resolution, 2014
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
HR 962/S 452 - Medicare Diabetes Prevention Act of 2013; HR 1257 Prevent Diabetes Medicare Act of 2013; HR 1274/S 945 Access to Quality Diabetes Education Act of 2013; HR 1588/ S 740 -- Medicare Drug Savings Act of 2013; HR 2415/ S 1184 - Treat and Reduce Obesity Act of 2013; HR 2663/S 1422 - Scoring of Preventive Health Savings
Medicare diabetes screening and self management
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 1919 - Safeguarding America's Pharmaceutical Act of 2013
HR 3204 - Drug Quality and Security Act, PL 113-54
FDA issues regarding biosimilar products; 340B program matters
Agencies Lobbied
U.S. Senate
3rd Quarter, 2013
In Q3, SLC Health Strategies, LLC lobbied for Novo Nordisk Pharmaceuticals, Inc. , earning $22,500. The report was filed on Oct. 20, 2013.
Original Filing: 300601400.xml
Lobbying Issues
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014
H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033
H. J. Res. 59 -- Continuing Appropriations Resolution, 2014
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
HR 962/S 452 Medicare Diabetes Prevention Act of 2013; HR 1257 - Prevent Diabetes in Medicare Act of 2013; HR 1247/S 945 - Access to Quality Diabetes Education Act of 2013; HR 2663/ S 1422 Scoring of Preventive Health Savings; and
S 1284 - Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act of 2014, specifically NDPP funding
Agencies Lobbied
U.S. Senate
Lobbying Issues
National Diabetes Prevention Program funding -- S 1284 - Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act of 2014
Implementation of the Affordable Care and Health Care & Education Affordability Reconciliation Act of 2010 (PL 111-148 and 111-152); diabetes screening
Human growth hormone and rare disease matters
HR 1074/S 539 - National Diabetes Clinical Care Commission Act of 2013
HR 1247/S 945 - Access to Quality Diabetes Education Act of 2013
HR 1915/S 907 - Gestational Diabetes Act of 2013
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014
H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033
H. J. Res. 59 -- Continuing Appropriations Resolution, 2014
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
HR 962/S 452 - Medicare Diabetes Prevention Act of 2013; HR 1257 Prevent Diabetes Medicare Act of 2013; HR 1274/S 945 Access to Quality Diabetes Education Act of 2013; HR 1588/ S 740 -- Medicare Drug Savings Act of 2013; HR 2415/ S 1184 - Treat and Reduce Obesity Act of 2013; HR 2663/S 1422 - Scoring of Preventive Health Savings
Medicare diabetes screening and self management
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 1919 - Safeguarding America's Pharmaceutical Act of 2013
HR 3204 - Drug Quality and Security Act
FDA issues regarding biosimilar products; 340B program matters
Agencies Lobbied
U.S. Senate
2nd Quarter, 2013
In Q2, SLC Health Strategies, LLC lobbied for Novo Nordisk Pharmaceuticals, Inc. , earning $22,500. The report was filed on July 19, 2013.
Original Filing: 300579651.xml
Lobbying Issues
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal year 2014
H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY '15 through 2033
In all of the above the specific issues included potential medicare offsets that might be applied to prescription drugs as well as funding for the National Diabetes Prevention Program
HR 962/S 452 Medicare Diabetes Prevention Act of 2013; HR 1257 - Preventing Diabetes in Medicare Act of 2013; HR 1274/S 945 - Access to Quality Diabetes Education Act of 2013; HR 2663 -- Scoring of Preventive Health Savings; and S. 1284 -- Departments of Labor, Health and Human Services, and education and Related Agencies Appropriations Act, 2014, specifically NDPP funding
Agencies Lobbied
U.S. Senate
Lobbying Issues
The National Diabetes Prevention Program funding -- S. 1284 Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2014; Implementation of the Affordable Care and Health Care & Education Affordability Reconciliation Act of 2010 ( PL 111-148 and 111-152); diabetes screening, death certificate reporting and medical education related to diabetes; HR 1074/S 539 -- the National Diabetes Clinical Care Commission Act; HR 1915/S 907 -- Gestational Diabetes Act of 2013; human growth hormone and rare disease matters
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014
H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY '15 through 2033
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs; HR 962/S 452 -- Medicare Diabetes Prevention Act of 2013; HR 1257 Prevent Diabetes Medicare Act of 2013; HR 1274/ S 945 -- Access to Quality Diabetes Education Act of 2013; Medicare diabetes screening and self management; HR 1588/S 740 -- Medicare Drug Savings Act of 2013; S 1184/HR 2415 -- Treat and Reduce Obesity Act of 2013; HR 2663 -- Scoring of Preventive Health Savings
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 1919 -- Safeguarding America's Pharmaceutical Act of 2013; FDA issues regarding biosimilar products; 340B program
Agencies Lobbied
U.S. Senate
1st Quarter, 2013
In Q1, SLC Health Strategies, LLC lobbied for Novo Nordisk Pharmaceuticals, Inc. , earning $22,500. The report was filed on April 21, 2013.
Original Filing: 300558878.xml
Lobbying Issues
S. Con. Res 8 -- Concurrent Resolution on the Budget For Fiscal Year 2014
H Con Res 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 15 through 2033
HR 933 -- Consolidated and Further Continuing Appropriations Act, 2013
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs as well as funding for the National Diabetes Prevention Program
HR 962/S 452 - Medicare Diabetes Prevention Act of 2013; HR 1257 Preventing Diabetes in Medicare Act of 2013;HR 1274 - Access to Quality Diabetes Education Act of 2013; Medicare diabetes screening and self management
Legislation (not yet introduced) regarding prevention/health related scoring
Medicare and Medicaid drug rebate matters
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 8 American Taxpayer Relief Act (specifically the Special Diabetes Program reauthorization); the National Diabetes Prevention Program; implementation of the Affordable Care and Health Care & Eduction Affordability Reconciliation Act of 2010 (PLs 111-148 and 111-152); diabetes screening, death certificate reporting and medical education related to diabetes; HR 1074/539, the National Diabetes Clinical Care Commission Act; gestational diabetes; and human growth hormone/rare disease matters
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. Con. Res 8 -- Concurrent Resolution on the Budget For Fiscal Year 2014
H Con Res 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 15 through 2033
HR 933 -- Consolidated and Further Continuing Appropriations Act, 2013
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugsHR 962/S 452 - Medicare Diabetes Prevention Act of 2013; HR 1257 Preventing Diabetes in Medicare Act of 2013;HR 1274 - Access to Quality Diabetes Education Act of 2013; Medicare diabetes screening and self management
Legislation (not yet introduced) regarding prevention/health related scoring
Medicare and Medicaid drug rebate matters
Agencies Lobbied
U.S. Senate
Lobbying Issues
FDA "track and trace" legislation, yet to be introduced; FDA issues regarding biosimilar product; 340B program matters, S 622 Animan Drug and Animal Generic Drug User Fee Reauthorization Act 2013
Agencies Lobbied
U.S. Senate
1st Quarter, 2013
SLC Health Strategies, LLC filed a lobbying registration on Jan. 19, 2013 to represent Novo Nordisk Pharmaceuticals, Inc., effective Jan. 3, 2013.
Original Filing: 300535904.xml
Issue(s) they said they’d lobby about: Health program appropriations/budget, health care reform implementation, diabetes research, Medicare/Medicaid coverage and reform matters, prescription drug/pharmaceutical/Food and Drug Administration matters .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...